Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3251296 | 0.82 | OPRM1 (0.34) | CYP1A2KDM4EKMT2AOPRM1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL21840084 | 0.79 | KDM4E (0.34) | CYP1A2PKMKDM4EKMT2AHRH4 | |
| 4,4-Difluoro-Piperidinium SCHEMBL28257455 | 0.78 | CYP1A2 (0.33) | CYP1A2PKMKDM4EKMT2AHRH4 | |
| Trifluoroacetic Acid SCHEMBL5035153 | 0.76 | CYP1A2 (0.42) | CYP1A2KMT2A | |
| Trifluoroacetic Acid SCHEMBL3332360 | 0.76 | HRH4 (0.34) | CYP1A2PKMKDM4EKMT2AHRH4 | |
| Trifluoroacetic Acid SCHEMBL3335470 | 0.74 | OPRM1 (0.33) | PKMKDM4EKMT2AHRH4OPRM1 | |
| Trifluoroacetic Acid SCHEMBL347581 | 0.74 | CYP1A2 (0.41) | CYP1A2KMT2A | |
| Trifluoroacetic Acid SCHEMBL4713905 | 0.73 | CYP1A2 (0.49) | CYP1A2PKMKMT2A | |
| SCHEMBL11082258 | 0.72 | CYP1A2 (0.36) | CYP1A2KDM4EKMT2AOPRM1 | |
| Trifluoroacetic Acid SCHEMBL3471327 | 0.72 | TSHR (0.38) | PKMHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2142537-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008115973-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | CYP1A2 3182/4885HSD11B1 4173/4885PKM 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.